Objective To evaluate the diagnostic value of gene testing in familial hypercholesterolemia(FH)in patients with premature myocardial infarction(PMI).Methods This study was a single center cross-sectional study.A retro...Objective To evaluate the diagnostic value of gene testing in familial hypercholesterolemia(FH)in patients with premature myocardial infarction(PMI).Methods This study was a single center cross-sectional study.A retrospective analysis was made on PMI patients who visited the People's Hospital of Peking University from May 1,2015 to March 31,2017.Clinical data of patients were collected and gene testing of FH related genes lowdensity lipoprotei1nreceptor(LDLR),proprotein convertase subtilisin/kexin type 9(PCSK9),apolipoprotein B(APOB)and low density lipoprotein receptor adaptor protein 1(LDLRAP1)was carried out.Clinical diagnosis of FH patients was performed using Simon Broome criteria,DLCN criteria,and FH Chinese expert consensus.Results There were 188 males(83.6%)among 225 PMI patients,and the age of the first myocardial infarction was(46.6±7.2)years old.Ten patients carried FH pathogenic or possibly pathogenic mutations(4.4%).Compared with Simon Broome standard,DLCN standard and FH Chinese expert consensus,gene testing increased the diagnostic rate of FH by 53.3%,33.3%and 42.1%respectively.展开更多
目的探讨瑞舒伐他汀是否作用于淋巴系统,影响淋巴系统介导的胆固醇逆转运发挥抗动脉粥样硬化作用。方法使用48只高脂饮食饲养载脂蛋白E-/-小鼠构建动脉粥样硬化模型。随机分为4组,每组12只,分别予瑞舒伐他汀、血管内皮生长因子-C(VEGF-C...目的探讨瑞舒伐他汀是否作用于淋巴系统,影响淋巴系统介导的胆固醇逆转运发挥抗动脉粥样硬化作用。方法使用48只高脂饮食饲养载脂蛋白E-/-小鼠构建动脉粥样硬化模型。随机分为4组,每组12只,分别予瑞舒伐他汀、血管内皮生长因子-C(VEGF-C)、瑞舒伐他汀+VEGF-C抑制剂作为实验组,对照组无干预措施。8周后检测小鼠主动脉斑块面积,淋巴液内高密度脂蛋白胆固醇(HDL-C)含量、腘窝淋巴管引流外周Evans蓝的功能、淋巴系统转运外周细胞膜红色荧光探针标记高密度脂蛋白(HDL)的能力。随后分别检测不同浓度瑞舒伐他汀对淋巴内皮细胞增殖、迁移、成管功能的影响和对淋巴内皮细胞上B类1型清道夫受体(scavenger receptor class B type 1,SR-B1)表达的影响。结果与对照组相比,瑞舒伐他汀和VEGF-C可以减小主动脉动脉粥样硬化斑块面积(P<0.05)。在瑞舒伐他汀他汀基础上加用VEGF-C抑制剂,主动脉内斑块面积增加(P<0.05)。与对照组相比,瑞舒伐他汀可以增加小鼠淋巴液内HDL-C含量(P<0.05),增强淋巴管引流功能,增强淋巴系统转运组织液中HDL的能力。与对照组相比,VEGF-C增加小鼠淋巴液内HDL-C的含量(P<0.01)、增强腘窝淋巴管引流功能、增强淋巴系统转运HDL的能力。在瑞舒伐他汀基础上加用VEGF-C抑制剂,淋巴液中HDL-C含量减少、腘窝淋巴管出现引流中断,淋巴系统转运HDL的能力降低。免疫印迹试验结果显示,瑞舒伐他汀可以增加SR-B1的蛋白表达。结论瑞舒伐他汀可促进淋巴内皮细胞的增殖、迁移和成管;同时促进淋巴内皮细胞上SR-B1的表达,从而增强淋巴系统介导的胆固醇逆转运,发挥抗动脉粥样硬化作用。展开更多
文摘Objective To evaluate the diagnostic value of gene testing in familial hypercholesterolemia(FH)in patients with premature myocardial infarction(PMI).Methods This study was a single center cross-sectional study.A retrospective analysis was made on PMI patients who visited the People's Hospital of Peking University from May 1,2015 to March 31,2017.Clinical data of patients were collected and gene testing of FH related genes lowdensity lipoprotei1nreceptor(LDLR),proprotein convertase subtilisin/kexin type 9(PCSK9),apolipoprotein B(APOB)and low density lipoprotein receptor adaptor protein 1(LDLRAP1)was carried out.Clinical diagnosis of FH patients was performed using Simon Broome criteria,DLCN criteria,and FH Chinese expert consensus.Results There were 188 males(83.6%)among 225 PMI patients,and the age of the first myocardial infarction was(46.6±7.2)years old.Ten patients carried FH pathogenic or possibly pathogenic mutations(4.4%).Compared with Simon Broome standard,DLCN standard and FH Chinese expert consensus,gene testing increased the diagnostic rate of FH by 53.3%,33.3%and 42.1%respectively.
文摘目的探讨瑞舒伐他汀是否作用于淋巴系统,影响淋巴系统介导的胆固醇逆转运发挥抗动脉粥样硬化作用。方法使用48只高脂饮食饲养载脂蛋白E-/-小鼠构建动脉粥样硬化模型。随机分为4组,每组12只,分别予瑞舒伐他汀、血管内皮生长因子-C(VEGF-C)、瑞舒伐他汀+VEGF-C抑制剂作为实验组,对照组无干预措施。8周后检测小鼠主动脉斑块面积,淋巴液内高密度脂蛋白胆固醇(HDL-C)含量、腘窝淋巴管引流外周Evans蓝的功能、淋巴系统转运外周细胞膜红色荧光探针标记高密度脂蛋白(HDL)的能力。随后分别检测不同浓度瑞舒伐他汀对淋巴内皮细胞增殖、迁移、成管功能的影响和对淋巴内皮细胞上B类1型清道夫受体(scavenger receptor class B type 1,SR-B1)表达的影响。结果与对照组相比,瑞舒伐他汀和VEGF-C可以减小主动脉动脉粥样硬化斑块面积(P<0.05)。在瑞舒伐他汀他汀基础上加用VEGF-C抑制剂,主动脉内斑块面积增加(P<0.05)。与对照组相比,瑞舒伐他汀可以增加小鼠淋巴液内HDL-C含量(P<0.05),增强淋巴管引流功能,增强淋巴系统转运组织液中HDL的能力。与对照组相比,VEGF-C增加小鼠淋巴液内HDL-C的含量(P<0.01)、增强腘窝淋巴管引流功能、增强淋巴系统转运HDL的能力。在瑞舒伐他汀基础上加用VEGF-C抑制剂,淋巴液中HDL-C含量减少、腘窝淋巴管出现引流中断,淋巴系统转运HDL的能力降低。免疫印迹试验结果显示,瑞舒伐他汀可以增加SR-B1的蛋白表达。结论瑞舒伐他汀可促进淋巴内皮细胞的增殖、迁移和成管;同时促进淋巴内皮细胞上SR-B1的表达,从而增强淋巴系统介导的胆固醇逆转运,发挥抗动脉粥样硬化作用。
